Dallas, Texas 04/28/2014 (FINANCIALSTRENDS) – The share price of Cesca Therapeutics Inc (NASDAQ:KOOL) which is a medical equipment and appliances manufacturer jumped up by a hugely impressive 28.7 percent during trading on 24th April on the back of positive coverage initiation by analyst firm Maxim Group. The positive coverage led to the investor community flocking to buy the stock on Thursday. On Friday, 24th April, the stock reversed some of the gains as investors booked profits and traded 7.2 percent during trading on 25th April.
The positive coverage initiated by Maxim Group comes on the back of major structural changes the company has made to its go to market strategy and has followed this up with a complete realignment of its sales, marketing and R&D teams. Some the key highlights to these structural changes are given below.
Cesca Therapeutics Inc (NASDAQ:KOOL) has brought in the services of Tim Lee, who is a long time veteran of the bio tech sector as the Director of International Sales. His team is expected to deepen the market and establish its cord blood business practice as a standalone revenue yielding stream. This move has been coupled with appointing its current VP of Commercial Operations Mr Hal Baker as an external consultant, so that he can help the new sales Director seamlessly assume his new role and proper knowledge transfer happens. The Director of sales would be reporting to the Company President Ken Harris.
The new release from Cesca Therapeutics Inc (NASDAQ:KOOL) goes on to add that, “In the newly formed role, Director of International Sales, Mr. Lee’s primary focus will be to lead global cord blood product sales and services. In addition, as Cesca’s clinical programs reach therapeutic market commercialization, Mr. Lee will work directly with our President, Ken Harris, to develop and implement the sales and marketing resources to commercialize and scale these programs”